Cholera rapid diagnostic tests at the host-microbe interface: Key Considerations for Global Deployments

Authors

S. M. Ahmed[1*†], Md. Abu Sayeed[2†], I. Sriguha[2], E. T. Cato[2], A. Creasy-Marrazzo[2], K. Islam[3], Md. I.UL. Khabir[3], Md. T. R. Bhuiyan[3], Y. Begum[3], Md. Taufiqul Islam[3], Zahid Hasan Khan[3], E. Freeman[2], A. Vustepalli[2], L. Brinkley[2], M. Kamat[4], L. S. Bailey[4], N. Madi[5,6], F. Qadri[3], B. J. Shapiro[5,6], D. T. Leung, K. B. Basso[4], D. A. Sack[7], J. R. Andrews[9], A. I. Khan[3*], E. J. Nelson[2*]

Affiliations

[1] Department of Epidemiology, Emory University, Atlanta, GA, USA
[2] Departments of Pediatrics and Environmental and Global Health, University of Florida, Gainesville, FL, USA
[3] Infectious Diseases Division, International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b), Dhaka, Bangladesh
[4] Department of Chemistry, University of Florida, Gainesville, FL, USA
[5] Department of Microbiology & Immunology, McGill University, Montréal, Canada
[6] McGill Centre for Microbiome Research, McGill University, Montréal, Canada
[7] Department of International Health, Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland, USA
[8] Department of Internal Medicine, Spencer Fox Eccles School of Medicine at the University of Utah, Salt Lake City, Utah, USA
[9] Division of Infectious Diseases and Geographic Medicine, School of Medicine, Stanford University, Stanford, California

[†] Co-first authorship
[*] Corresponding authors

Email: sharia.m.ahmed@emory.edu, ashrafk@icddrb.org; eric.nelson@ufl.edu

Keywords

Cholera, diarrhoea, diarrhea, *Vibrio cholerae*, bacteriophage, phage, antibiotics, antimicrobial resistance, AMR, rapid diagnostic test, RDT, Bangladesh, outbreak

Enumerations

Abstract: #words (265; 250 max). Summary: 234 words (optional).
Manuscript: 3335 words (3500 max).
Inserts: 1 Figures. 6 Tables
Supplement: 3 Figures, 4 Tables
References: 56 (30 max)

ABSTRACT

Effective cholera outbreak response requires accurate bedside rapid diagnostic tests (RDTs) because access to laboratories is limited. Formative studies suggest cholera diagnostics have multiple vulnerabilities, including predation by virulent bacteriophage ('phage') specific to *Vibrio cholerae* (*Vc*). Here we conducted a prospective nationwide study in Bangladesh among over 2000 patients with diarrheal disease to characterize how these vulnerabilities impact RDT performance. Assays included culture, qPCR, metagenomics and mass spectrometry. With the current gold standard of culture or qPCR *Vc* positivity, we initially found no significant effect of phage on RDT performance. When the standard was expanded to include phage, there was a small decrease in RDT sensitivity. In contrast, significant increases in sensitivity and specificity were found among patients with moderate or severe dehydration. Using the expanded definition, the odds of RDT positivity among cholera patients decreased by 63% (OR 0.377; 95%CI 0.217-0.642; $P<0.001$) with phage exposure. The effect was most robust among patients with severe dehydration. Furthermore, the odds of RDT test positivity among those samples with phage increased by 14 times (OR 14.7; 95%CI 2.83-117) if the infecting *Vc* strain harbored phage resistance factors. Antibiotic exposure was common which limited interpretation. Applying these findings, we estimated that restricting RDT use to severe patients with no known antibiotic exposure increases relative sensitivity by 50% with and without the expanded case definition. Despite this maneuver, the RDT remains with limitations that require consideration when optimizing global deployment strategies. The impact of these findings likely extends to other diseases where diagnostics share similar vulnerabilities.

Summary.

Effective management, control and elimination of cholera requires accurate bedside rapid diagnostic tests (RDTs) because access to laboratory diagnostics is often limited. In response, international agencies have operationalized a global RDT deployment to address this logistical problem. Unfortunately, cholera diagnostic performance, including that of RDTs, are likely vulnerable to bacteriophage (‘phage’) predation and antibiotic exposures. This vulnerability has real-world consequences for outbreak response and calls into question the value of RDTs in their current form and method of use. In response, our objective was to determine if phage and antimicrobials indeed impact RDT performance and identify ways to better deploy RDTs and interpret results. We found RDT performance was not affected overall with phage exposure. However, we discovered that performance was positively associated with disease severity, and among severely dehydrated cholera patients, phage did have a significant negative effect. Antibiotic exposure was pervasive which limited interpretation. Among cholera patients with phage, the odds of RDT test positivity increased when the pathogen (*Vc*) harbored phage resistance factors. We explored the effects on RDT performance by including phage detection as a proxy for pathogen detection. We estimate that changing to a mode of restricted use in which RDTs are performed only on dehydrated patients, who report no antibiotic exposure, improves the relative sensitivity of the test by fifty percent. However, this maneuver neglects the poor performance among patients without dehydration. The significance of these findings may extend broadly to other diseases where diagnostics share similar vulnerabilities.

INTRODUCTION

Cholera causes an estimated 1.3 – 4 million symptomatic cases and 21,000 – 143,000 deaths annually[1]. Since the COVID-19 pandemic, cholera outbreaks expanded to over 44 countries[2] and the World Health Organization (WHO) declared a global emergency at its highest level (grade 3)[3]. In both endemic and non-endemic regions facing this crisis, access to 'gold-standard' culture and molecular based diagnostics at conventional laboratories is limited which can impede effective response. Accurate bedside rapid diagnostic tests (RDTs) offer a promising solution to this problem. In response, international agencies have subsequently operationalized large RDT deployments[4] for epidemiologic applications that include surveillance and optimization of vaccination campaigns[5,6].

Cholera is an acute watery diarrheal disease caused by the Gram-negative facultative anaerobe *Vibrio cholerae (Vc)*. Case fatality rates historically rose above 20% before intravenous fluids, but in the modern era can fall to less than 1% with use of oral rehydration solution (ORS) alone[7]. The current paradigm is that susceptible individuals become infected after exposure to contaminated food, fomites, or water. The exact infectious dose in humans is unknown and likely varies. In an infant mouse model, the infectious dose may be as low as 20 cells when the inoculum is human-shed *Vc*[8]. The infection may manifest in asymptomatic or symptomatic disease. The ratio of symptomatic to asymptomatic cases is thought to vary widely. In the endemic setting of Bangladesh, it is estimated there are 820 asymptomatic infections (or exposures) per symptomatic case[5].

Factors that influence cholera severity across the asymptomatic to symptomatic spectrum includes the degree of prior exposure to *Vc*[7], antimicrobial exposures[9], and effective predation by virulent bacteriophage (phage)[10]. The WHO Global Task Force on Cholera Control (GTFCC) recommends antibiotic treatment (doxycycline (DOX), azithromycin (AZI), or ciprofloxacin (CIP)) for more severe cases as a supportive maneuver [11-14]. In practice, mass spectrometry revealed that nearly all cholera patients in a setting like Bangladesh shed diverse antibiotics despite only half reporting exposure[10,15,16]. Antibiotic resistance is common and spreads globally as cholera spreads[17,18]. Virulent phages specific to *Vc* are relatively common and limited in number (ICP1, 2, 3)[19-23]. *Vc* can harbor arrays of phage defense mechanisms, including BREX, on a mobile integrative and conjugative element (ICE) which also harbors antibiotic resistance factors. Phage in turn can harbor cognate antidefenses[24-27]. Phage can also act synergistically or antagonistically with antibiotics to kill bacterial prey[28,29]. While a phenotype called hyper-infectivity is thought to accelerate outbreaks, phage predation is proposed to quench outbreaks, although data are limited[30-35].

Culture and molecular (e.g., PCR, qPCR) assays are considered ‘gold-standards’ for cholera diagnostics[36,37]. Adjunct commercialized RDTs typically are lateral flow devices (‘dipsticks’) that rely on O-specific polysaccharide (OSP) specific antibodies (Abs)[37-39]. Guidelines restrict RDTs to epidemiologic and not clinical applications because of variable performance with sensitivity ranging from 58-100% and specificity from 71-100%[37,40-42]. Attempts to increase RDT performance by altering protocols and assembly have had limited gains to extend their use to clinical decision making[40,41,43]. Explanations for the varied sensitivity include variations in disease severity,

antimicrobial exposure, and phage predation[36,37,9,44]. We previously found that the odds of RDT positivity among cholera patients was reduced by more than 80% when phage or antibiotics were detected[9]. This vulnerability calls into question the value of RDTs in their current form and method of use. Determining antimicrobial effects on performance may offer opportunities to optimize deployment and extend use to clinical decision-making.

Our objective herein was to evaluate two primary hypotheses: (i) Virulent phage and antibiotic exposure negatively impact RDT performance. (ii) RDT performance positively correlates with disease severity, defined using the WHO dehydration classifications of mild, moderate and severe[45]. These two hypotheses are connected by target concentration. The mechanisms of the first hypothesis might be a decrease in *Vc* targets below the RDT limit of detection (LOD) in the first hypothesis versus an increase in *Vc* targets above the LOD in the second hypothesis [10,46]. To test these hypotheses, we analyzed data from a prospective clinical study conducted across Bangladesh whereby stool samples were collected from patients admitted with diarrheal disease at district hospitals[47]. Clinical metadata were paired with microbiologic and molecular data to detect and quantify *V. cholerae* and associated phage; mass spectrometry was conducted on select samples to objectively assess antibiotic effects. The results support our hypotheses exposing critical RDT limitations while also revealing potential approaches that could optimize global RDT deployments.

MATERIALS AND METHODS

Ethics Statement. Samples, and associated clinical data, were collected within two previously published IRB approved clinical studies in Bangladesh: (i) The National

Cholera Surveillance (NCS) study (icddr,b ERC/RRC PR-15127)[48] and (ii) The mHealth Diarrhea Management (mHDM) cluster randomized controlled trial (IEDCR IRB/2017/10; icddr,b ERC/RRC PR-17036; University of Florida IRB 201601762) [47].

Study Design. The parent study for this secondary analysis was a prospective longitudinal study of patients admitted with diarrhea at five Bangladesh Ministry of Health and Family Welfare district hospitals (both NCS and mHDM sites) and two centralized NCS hospitals (BITID; icddr,b) (**Fig S1)**. Sites were distributed nation-wide[49]. Samples were collected from March 2018 to December 2018; samples were collected until April 2019 at one site (icddr,b).

Laboratory procedures. Stool samples were collected at admission. Aliquots for subsequent culture at a central laboratory via standard methods[50] were stabbed into Cary-Blair transport media. Aliquots for molecular analysis were preserved in 75% RNAlater (Invitrogen); total nucleic acid (tNA) was extracted using standard methods. Criteria and methodology for shotgun metagenomic sequencing for a subset of samples was described previously[10]; in brief, sequenced samples were (i) culture positive for *Vc*, (ii) phage (ICP1,2,3) positive by PCR among culture-negative samples, or (iii) *Vc* positive by PCR (*ompW* target) among a random 10% of those samples negative by culture for *Vc* and by PCR for phage (**Fig S2**). Quantitative PCR (qPCR) was also subsequently performed on all available samples to enumerate absolute abundances of *Vc* (*tcpA*), ICP1 (GP58.2), ICP2 (GP24), and ICP3 (GP19) using methods previously described[10]. Estimates for CFU/ml were derived using the qPCR Ct values from standard curves of serial dilutions of cultured *V. cholerae*.

Those available culture-positive cholera fecal samples identified for metagenomics were also analyzed by LC-MS/MS (LCMS) for antibiotics using methods previously described[10]. Common antibiotics targeted based on prior research[10,15] included ciprofloxacin, doxycycline/tetracycline, and azithromycin, metronidazole and nalidixic acid were analyzed qualitatively. For quantitative analysis of ciprofloxacin, doxycycline/tetracycline, and azithromycin, standard curves were prepared by dilution series of the native and isotopic forms of targets. Each stool sample was spiked with the isotopic mixture as an internal reference control. Quantitative results were binned by effective concentration and ineffective concentration; the definition of effective concentration was based on the lowest minimal inhibitory concentration in a prior strain collection[51].

Stool samples were tested by Cholkit (Incepta Pharmaceuticals, Bangladesh), an RDT that targets the detection of *V. cholerae* O1 LPS using a standardized method[39,52]. In brief, five drops of watery stool were added to the diluent supplied in a microcentrifuge tube. The RDT strip was then dipped into the stool-diluent mixture for 15 minutes. *V. cholerae* O1 detection was confirmed ‘by eye’ for the appearance of both test and control lines[39]. Solid stools were not tested; cholera RDTs in general, including the Cholkit, are not designed to test solid stools.

Statistical analyses. Statistics and visualizations were done in GraphPad Prism version 10.2.3 and R version 4.4.2[53]. The “Eulerr” package was used to create Figure 1a for samples with all relevant test results available[54]. Test performance metrics (sensitivity, specificity, positive predictive value, negative predictive value) and corresponding exact binomial confidence limits were calculated in the “epiR” package[55].

Standardized predictive values were calculated by using the observed diagnostic sensitivity and specificity in the given subgroup and calculating the predictive value that would have been observed if disease prevalence was 50% in that subgroup. We used unadjusted generalized linear models with a binomial error distribution and logit link to estimate odds ratios and corresponding 95% confidence intervals. Fisher's exact test was used to calculate p-values where indicated.

RESULTS

Study overview. A total of 2574 participants were enrolled at seven hospitals across Bangladesh from March to December 2018, with one stool sample collected from each participant (**Figs S1 and S2**). Enrollment continued at one site (icddr,b) until April 2019. Although RDTs were not performed at this site, samples were included to better assess phage and *Vc* relationships by qPCR (**Fig 1)**. RDTs were performed on each of the remaining 2180 samples of which all had culture and 2078 had *Vc* qPCR **(Table 1)**. Specific to testing our two hypotheses: (i) ICP1, ICP2, and ICP3 were detected among 137, 10, and 86 participants, respectively, and (ii) the number of participants with mild, moderate and severe dehydration was 392, 1193 and 493, respectively. Metagenomic sequencing was attempted and successful on 344/389 cholera samples as previously described[10] and presented in **Fig S2**. From these data, metagenomic assembled genomes (MAGs) were constructed for *Vc.* MAGS (218) were screened for the phage resistance factor BREX which resides on different types of the mobile genetic element ICE[10] (Ind5, Ind6). In this sample group, 67, 22, and 30 had Ind5, Ind6, and No ICE, respectively. LCMS for antibiotic detection was attempted and successful on all culture positive samples and a subset of culture negative samples (446) [10,15,51] **(Fig S2).**

Characterization and comparison of assays for *Vc* detection. Among samples with all assays performed, there was discordance in *Vc* detection by assay type (**Fig 1A**). Out of 2078 samples with both *Vc* culture and qPCR, only 5.8% (120) of samples were positive for *Vc* by both culture and qPCR. An additional 13.2% (274) of samples were negative by culture and positive by qPCR, and 2.6% (55) of samples were positive by culture and negative by qPCR. The concentration of *Vc* at which 50% of the RDTs tested positive (diagnostic dose 50 or 'DD_{50}') was 1.93 x 10^8 CFU/ml; The percentage of positive RDTs increased with *Vc* concentration binned by order of magnitude (**Fig 1B**).

Distribution of phage among samples with and without *Vc*. Among samples with all assays performed, ICP1, ICP2 and ICP3 were detected by qPCR in 137, 10 and 76 samples, respectively (**Table 1**). These analyses include samples that were positive or negative for *Vc*. In the absence of *Vc* (culture or qPCR), ICP1, ICP2, and ICP3 were detected in 2.1% (43), 0.2% (4), and 3.1% (64) of samples respectively (**Fig 1A**); unless specified, analyses focused on ICP1 and ICP3 because of the larger sample sizes. We analyzed quantitative associations between phage and *Vc.* Data were visualized in quadrants by *Vc* and/or phage detection using a Ct threshold of 28 (**Fig 1C, D**). Samples that did not have RDT results (gray 'x') were included to better elicit patterns in the data. For both ICP1 and ICP3, increasing *Vc* detection was associated with increasing phage detection. Among those samples with RDT results, the percentages of RDT positive samples are shown in quadrant. The quadrants with the least percentage of RDT positive samples were those with phage detection alone.

Effect of phage predation on RDT performance. Among *Vc* positive samples by qPCR or culture, RDT sensitivity (46%) and specificity (85%) did not differ when phage positive samples were excluded (**Table 2**). While PPV and NPV were higher and lower, respectively among samples with ICP1 only compared to other groups, this effect was driven by the different cholera prevalence between groups, and disappeared once predictive values were assessed at a standardized prevalence. Among samples with ICP3, sensitivity decreased compared to samples without phage however confidence intervals overlapped. These initial findings did not strongly support our guiding hypothesis within the context of the current gold standard which excludes those samples with phage positivity alone. We therefore expanded the reference standard to include phage detection as a proxy for *Vc* given the phage are *Vc* specific. The inclusion of phage in the criteria had modest effects that did align with the hypothesis (**Table S1**); the sensitivity decreased from 0.46 (95%CI 0.41–0.51) to 0.38 (95%CI 0.34-0.42). In other words, we estimated RDTs would miss an additional 17% of 'true' cholera cases if the diagnostic reference standard were expanded to include "phage only" as cholera cases.

Effect of dehydration severity on RDT performance. We evaluated the impact of dehydration severity on RDT performance. The median concentrations of *Vc* (CFU/ml) derived from those samples positive by qPCR at mild, moderate or severe levels of dehydration were 3.25×10^7 (IQR 8.60×10^6 to 1.14×10^9), 1.05×10^8 (IQR 1.06×10^7 to 2.16×10^9) and 1.00×10^8 (IQR 8.34×10^6 to 4.41×10^9), respectively. In this context, RDT performance consistently increased sequentially from patients with mild to moderate to severe dehydration (**Table 3**). RDT sensitivity was 0.25 (95% CI: 0.16,

0.37) in those mildly dehydrated, compared to 0.63 (95% CI: 0.54, 0.71) in samples from severely dehydrated patients. Specificity also increased in samples from more severely dehydrated patients, but more modestly. Standardized predictive values, both positive and negative, also increased significantly in samples from severely dehydrated patients compared to mildly dehydrated patients.

Effect of phage on the RDT performance at different dehydration levels. We explored possible effect modification by dehydration level on the impact of phage on RDT performance **(Table 4)**. Among *Vc* positive patients (culture or qPCR), phage exposure was not associated with RDT positivity at any dehydration severity. When the case definition was expanded to include phage detection, the odds of RDT positivity were significantly lower in those with phage compared to those without phage (OR 0.377; 95%CI 0.217-0.642). This effect was observed among samples from moderately and severely dehydrated cases, but not from mildly dehydrated cases. The effect also differed by phage type used in the case definition. The effect of phage on RDT positivity was strongest when *Vc* positive was defined as positive by culture, qPCR, or ICP3 positive (OR 0.099; 95%CI 0.023-0.292). The effect modification by dehydration status was also strongest with this case definition.

Effect of phage resistance on RDT positivity. To evaluate phage effects from a microbiologic perspective, we tested if there was an association between phage resistance harbored by *Vc* and RDT positivity. Among samples with phage and metagenomic data in which *Vc* genomes were assembled, we found the odds of RDT positivity increased by 14 times (OR 14.7; 95%CI 2.83-117) when *Vc* harbored the phage resistance factors on the Ind5 and Ind6 mobile (ICE) elements **(Table 5)**.

Effect of antibiotic exposure on RDT performance. LCMS was used to objectively assess antibiotic exposure on select cholera samples (**Fig S2**) as previously described[10,15,51]. Discordance between self-reported and LCMS-detected antibiotic exposures were common (**Fig S3**). Among those with complete diagnostics (*n*=2078), approximately half of patients (46%; *n*=956) self-reported antibiotic exposure. Among the WHO recommended antibiotics, ciprofloxacin was the most commonly self-reported antibiotic (27%; 568) followed by azithromycin (14%; 289) with no participant self-reporting doxycycline use (**Table S2**). RDT performance was stable across all types of self-reported antibiotic exposure, including no self-reported antibiotic exposure. To take a more objective approach, LCMS was used to detect exposure to common antibiotics (CIP, AZI, DOX, metronidazole (MET), or nalidixic acid (NAL) detected in 81% (178/220) of samples tested (**Table S2**). The small proportion of samples assayed LCMS that did not have antibiotics limited analyses on the effects of antibiotics on RDT performance. Despite this challenge, RDT sensitivity among samples with AZI at or above the 'effective concentration' was 0.33 (95%CI 0.13-0.59) compared to 0.67 (95%CI 0.47-0.83) samples without antibiotic (**Table S2**). Among *Vc* positive samples, antibiotic resistance had no effect on the odds of RDT positivity with or without AZI exposure, however samples sizes were small (**Table S3**).

Estimates of RDT performance in different modes of deployment. We sought to estimate and compare RDT performance in different modes of deployment (**Table 6**). We considered an unrestricted mode in which all patients are tested. We compared this to a more restricted mode that would rely on data accessible at the bedside through the clinical history (self-reported antibiotic exposure) or the physical exam (dehydration

status). Despite phage detection not being accessible at the bedside, it is reasonable to consider it as a potential component to include in molecular diagnostic panels in the future. LCMS is too expensive and complex for consideration. In this context, we found that RDT sensitivity increased from 0.46 (95%CI: 0.41-0.51) among all patients to 0.69 (95%CI: 0.57-0.80) when use is restricted to patients that report no antibiotic exposure and have severe dehydration. When the case definition was expanded to include phage detection, RDT sensitivity also increased between restricted and unrestricted modes. Predictive values modestly increased with restricted modes, though were only significantly different for negative predictive values restricted to severely dehydrated cases.

DISCUSSION

Effective cholera control is aided by accurate bedside rapid diagnostic tests (RDTs). Here we conducted a secondary analysis of a prospective cohort study of patients with diarrheal disease to test if virulent bacteriophage (phage) impact RDT performance and determine if there are tractable approaches to optimize RDT use. With the current gold standard of culture or qPCR *Vc* positivity, we found no significant effect of phage on RDT performance. When the standard was expanded to include phage, there was a small decrease in RDT sensitivity. In contrast, significantly higher sensitivity and specificity were found among patients with moderate or severe dehydration. Using the expanded definition of including phage detection, the odds of RDT positivity among cholera patients decreased by 57% with phage exposure and the effect was most robust among patients with severe dehydration. These findings align with our guiding

hypotheses as well as pose intriguing questions on how one might apply these results to optimize RDT deployments.

Our first hypothesis was that virulent phage and antibiotic exposure negatively impact RDT diagnostic performance. RDT sensitivity and specificity were not appreciatively impacted when samples with phage were removed from the analysis. Among ICP1 positive samples, PPV and NPV increased and decreased respectively using the current gold standard case definition. This likely reflects an increased pretest probability for *Vc*; standardizing rates of *Vc* removed the effect. Among ICP3 positive samples, sensitivity and PPV were decreased however confidence intervals overlapped; standardizing rates of *Vc* removed the effect on PPV. We next expanded the case definition to include phage detection. Inclusion of phage in the diagnostic criteria had modest effects that aligned with our guiding hypotheses.

Our second hypothesis was that RDT performance positively correlates with disease severity. The rationale is based on our prior study of the predator (phage) prey (*Vc*) dynamics along the spectrum of disease severity; the study found high abundance of *Vc* was correlated with severe disease[10]. In contrast to the modest effects of phage, significant increases in sensitivity and specificity were found among patients with moderate or severe dehydration. Despite phage predation, this finding likely reflects that samples from more severe patients had higher concentrations of *Vc* at levels that we showed have a higher percentage of RDT positivity.

The lack of congruence between the assays performed may reflect complex underlying biologic events and not simply variation in assay assembly and manipulation. Mechanistically, we propose that false positive RDTs may be more common among

mild cases because the concentration of *Vc* is low and non-*Vc* microbiota is high which may increase cross-reactivity of the immunologic epitopes. Although cross-reactivity may occur using molecular assays, cross-reactivity for the qPCR primer set used for *Vc* and phages is well validated[10]; that said degradation of the nucleic acid impacts molecular assays which we mitigated by stabilizing the samples. Culture is a definitive assay for *Vc* but sensitivity can decrease because of processing delays, antibiotic exposure and possibly phage predation. In this context, we evaluated the interactions between phage predations and disease severity. Using the expanded case definition that includes phage detection, we found that the odds of RDT positivity among cholera patients decreased by 63% with phage exposure. The effect was most robust among patients with severe dehydration and varied by phage type; ICP3 decreased the odds of RDT positivity among cholera patients. One explanation for this effect of among severely dehydration patients with ICP3 is that there is simply more prey for the predator among severely dehydration patients and the effect size can be more easily detected. Among patients with mild disease, there may simply be insufficient *Vc* for the RDT to detect independent of phage predation.

Both clinicians and epidemiologists face two key questions based on these findings. The first question is whether to include phage detection in cholera diagnostic panels as a proxy for detection of the pathogen when phage degrade the pathogen below the limit of detection for a given assay. The benefits (e.g. overall increased case detection) versus risks (e.g. including increased cost) need consideration by both clinicians and epidemiologists. The second question is how to best validate and incorporate these findings as RDTs are being deployed globally to combat cholera. For

validation, studies in diverse clinical and epidemiologic scenarios are needed. For deployment, we estimated the effects of restricting RDT use to patients who report no antibiotic use and have severe dehydration. In this context, sensitivity had a relative increase of approximately 50%, independent of consideration of phage predation. This restriction may represent a strategy to conserve RDTs in resource limited situations. However, this restriction may also miss non-severe disease that might play an important role in transmission or mortality in the convalescent period.

These findings should be considered within the limitations of the study. First, LCMS was not performed on all samples because of logistical limitations. Among *Vc* or phage positive samples, LMCS found antibiotics were common and the distributions of samples were insufficient to disaggregate the effects of phage and antibiotics on RDT performance; restricting RDT use estimates to those without antibiotic exposure is empiric. Second, the recruitment and enrollment of patients within the parent clinical trial was based on the census of patients that sought care which represents a recruitment bias. Those patients that sought care were not considered representative of all infected individuals in the community. Third, clinical exams were conducted in district hospitals using WHO and Bangladesh Ministry of Health and Family Welfare guidelines. These guidelines have varied accuracy; this study would likely be improved by incorporating more accurate measures of dehydration[56]. Fourth, the approach had experimental limitations: The analyses excluded host factors such as innate and acquired immunity. Control assays were not performed on asymptomatic/healthy participants in the community. The enumeration of *Vc* with ‘phage resistance’ using ICE-Ind5 and ICE-Ind6 positivity was a proxy for direct detection of the BREX-mediated phage resistance

system[25]. Solid stools were not assayed. Despite these limitations, the findings provide important actionable insights. Future time-series studies of patients over the disease course and recovery period in endemic and non-endemic settings would assist testing our guiding hypotheses and address study limitations.

CONCLUSION

Herein, we found RDT performance was minimally impacted by phage overall and significantly increased among severely dehydrated patients. Expanding the case definition to include phage, the odds of RDT test positivity decreased significantly. We favor the expanded case definition that includes phage while recognizing the need for future investigation. Lastly, we provide estimates on the applied effects of restricted vs non-restricted RDT deployment. The significance of these findings may extend broadly to other disease where diagnostics share similar vulnerabilities.

Data availability. Upon request.

Code availability. Avail upon request.

Acknowledgements: We thank the patients for their participation. We thank the diligent clinical and laboratory team members who were essential to the success of the study. We are grateful to the Institute of Epidemiology, Disease Control and Research (IEDCR), Ministry of Health and Family Welfare, and Government of Bangladesh who collaborated on the original parent clinical studies. We are also grateful to the Governments of Bangladesh and Canada for providing unrestricted support to the icddr,b. We are grateful to B. Johnson and K. Berquist for their administrative guidance at the University of Florida.

Funding: The laboratory procedures were funded by a Wellcome Trust grant to EJN [DFID grant 215676/Z] and National Institutes of Health grants to KBB [S10 OD021758-01A1] and DS [R01 AI123422-06A1]. Statistical analysis was funded in part by a grant from the Thrasher Research Fund to SMA . The parent clinical study was supported by National Institutes of Health grants to EJN [R21TW010182]. The funders had no role in the study design, data collection, statistical analyses, decision to publish, or preparation of the manuscript.

Author contributions:

Conceptualization: SMA, MAS, FQ, JA, AIK, EJN

Implementation of clinical study: MAS, FQ, AIK, EJN

Lab procedures: MAS, ETC, ACM, KI, MIUK, MTRB, YB, EF, AV, LB, MK, LSB, EJN

Statistical analyses and visualizations: SMA, NM, BJS, JA, EJN

Funding acquisition: SMA, DS, KBS, EJN

Supervision: KBS, BJS, FQ, AIK, EJN

Writing – original draft: SMA, EJN

Writing – review & editing: SMA, MAS, DS, AKD, JA, FQ, AIK, EJN

Competing interests: Authors declare that they have no competing interests.

FIGURES

FIGURE 1



Fig. 1. Comparison of target detection by different diagnostics. A. Euler plot that approximates proportional distributions and overlaps between positive diagnostics. Given limitations with Euler plots, not all positive values or interactions are shown: *Vc* culture (n= 59/175; 34%), *Vc* qPCR (*tcpA*; n= 32/394; 8%), ICP1 qPCR (n= 9/193; 7%), ICP2 (n= 5/10; 50%), ICP3 (n= 12/86; 14%) and the RDT (n= 6/446; 1%). **B**. Linear regression analysis of relationship between $\log_{10}$ *Vc* abundance (CFU/ml) derived from *tcpA* qPCR and RDT positivity. Samples were binned into five groups based on *Vc* concentration: less than $1x10^7$, 1-9 x 10^7, 1-9 x 10^8, 1-9 x 10^9, and above $1x10^{10}$ CFU/ml. In a given group, each symbol is plotted by the median concentration (X coordinate) by the proportion of samples RDT positive (Y coordinate). The *Vc* dose at which 50% of RDTs ('DD_{50}') were positive (gray dotted line at 1.93 $x10^8$ CFU/ml). Line of best fit is shown and fit using least squares regression (95% CIs shown). **C.** Comparison of qPCR Ct values for *Vc* (*tcpA*) with ICP1. **D.** Comparison of qPCR Ct values for *Vc* (*tcpA*) with ICP3 (GP19). For C and D: Quadrants are demarcated by phage (Ph) and *Vc* positivity (+) with the percentage RDT positive per quadrant. Gray dotted lines = thresholds for positive (Ct = 28). "X" = no RDT performed; hollow colored circle = RDT+, hollow gray circle = RDT-. Tick shows dose at which 50% of all RDTs are positive (DD_{50}).

Table 1. Overview of participants characteristics by RDT result

Characteristic	RDT Negative *n*= 1632[a] (total)	RDT Positive *n*= 446[a] (total)
Site		
Habiganj[b] (#2)	328 (20.1%)	177 (39.7%)
Naogaon[b] (#4)	227 (13.9%)	48 (10.8%)
Patuakhali[b] (#5)	188 (11.5%)	40 (9.0%)
Comilla[b] (#15)	169 (10.4%)	18 (4.0%)
Kusthia[b] (#17)	458 (28.1%)	99 (22.2%)
Chittagong (BITID; #10)	262 (16.1%)	64 (14.3%)
Sex, n (%)		
Male (#1)	810 (49.6%)	226 (50.7%)
Female (#2)	822 (50.4%)	220 (49.3%)
Age (months), median (IQR)	300 (15.0-480)	240 (14.0-420)
Age, n (%)		
0-11 months	270 (16.5%)	78 (17.5%)
1-4 years	319 (19.5%)	82 (18.4%)
5-64 years	968 (59.3%)	277 (62.1%)
65+ years	75 (4.6%)	9 (2.0%)
Dehydration status		
Mild	302 (18.5%)	90 (20.2%)
Some	965 (59.1%)	228 (51.1%)
Severe	365 (22.4%)	128 (28.7%)
Culture, *n* (%)		
Negative	1574 (96.4%)	329 (73.8%)
Positive	58 (3.6%)	117 (26.2%)
qPCR, *n* (%)		
Vc (*tcpA*) negative	1426 (87.4%)	258 (57.8%)
Vc (*tcpA*) positive	206 (12.6%)	188 (42.2%)
ICP1 (GP58.2) negative	1544 (94.6%)	397 (89.0%)
ICP1 (GP58.2) positive	88 (5.4%)	49 (11.0%)
ICP2 (GP24) negative	1627 (99.7%)	441 (98.9%)
ICP2 (GP24) positive	5 (0.3%)	5 (1.1%)
ICP3 (GP19) negative	1557 (95.4%)	435 (97.5%)
ICP3 (GP19) positive	75 (4.6%)	11 (2.5%)
Self-reported antibiotic use		
No	877 (53.7%)	245 (54.9%)
Yes	755 (46.3%)	201 (45.1%)

[a] Values for those samples in which cultures, qPCR (*tcpA*, ICP1, ICP2, ICP3) and RDT were performed out of the given total. Excludes samples from Dhaka samples (n=394) because RDTs were not performed at this site

[b] Ministry of Health and Family Welfare, Government of Bangladesh District Hospitals. Icddr,b = International Centre for Diarrhoeal Disease Research, Bangladesh. BITID = Bangladesh Institute of Tropical Infectious Diseases.

Table 2. Effect of phage predation on RDT performance

Sample type	All	No phage [a]	ICP1 phage positive	ICP3 phage positive
Vc+/total (%)[b]	449 / 2078 (21.6)	345 / 1852 (18.6)	89 / 137 (65.0)	15 / 86 (17.4)
Sensitivity	0.46 (0.41, 0.51)	0.46 (0.40, 0.51)	0.49 (0.39, 0.60)	0.27 (0.08, 0.55)
Specificity	0.85 (0.84, 0.87)	0.85 (0.83, 0.87)	0.90 (0.77, 0.97)	0.90 (0.81, 0.96)
PPV_{obs}[c]	0.46 (0.42, 0.51)	0.41 (0.36, 0.46)	**0.90 (0.78, 0.97)**	0.36 (0.11, 0.69)
NPV_{obs}[c]	0.85 (0.83, 0.87)	0.87 (0.85, 0.89)	**0.49 (0.38, 0.60)**	0.85 (0.75, 0.92)
PPV_{50}[c]	0.76 (0.72, 0.79)	0.75 (0.71, 0.79)	0.83 (0.68, 0.93)	0.73 (0.45, 0.92)
NPV_{50}[c]	0.61 (0.59, 0.64)	0.61 (0.58, 0.64)	0.64 (0.53, 0.73)	0.55 (0.43, 0.67)

[a] ICP1, ICP2, and ICP3 not detected
[b] Number positive for *Vc by* culture or qPCR (*tcpA*) as the gold reference standard over total number samples in grouping
[c] Subscript indicates the proportion of samples that were gold-standard positive in the given group for the calculation of each predictive value, with "obs"=observed and "50"=50%. For example, PPV_{50} or standardized positive predictive value indicates the positive predictive value of RDT in each group if 50% of that group was gold-standard positive for cholera.

Table 3. Effect of dehydration severity on RDT performance

	Mild (comparator)[a]	Moderate[a]	Severe[a]
Vc+/total (%)[b]	75 / 392 (19.1)[c]	236 / 1193 (19.8)[c]	138 / 493 (28.0)[c]
Sensitivity	0.25 (0.16, 0.37)	0.43 (0.36, 0.49)	**0.63 (0.54, 0.71)**
Specificity	0.78 (0.73, 0.82)	**0.87 (0.84, 0.89)**	**0.88 (0.85, 0.92)**
PPV_{obs}[d]	0.21 (0.13, 0.31)	**0.44 (0.38, 0.51)**	**0.68 (0.59, 0.76)**
NPV_{obs}[d]	0.81 (0.77, 0.86)	0.86 (0.84, 0.88)	0.86 (0.82, 0.89)
PPV_{50}[d]	0.53 (0.42, 0.63)	**0.76 (0.71, 0.81)**	**0.85 (0.78, 0.89)**
NPV_{50}[d]	0.51 (0.45, 0.57)	**0.60 (0.57, 0.64)**	**0.71 (0.65, 0.76)**

[a] Mild, moderate and severe dehydration approximate 0-4%, 5-9% and 10%+ loss to normal body due to diarrheal fluid loss per WHO guidelines.
[b] Number positive for *Vc by* culture or qPCR (*tcpA*) as the gold reference standard over total number samples in grouping
[c] The concentration of *Vc* derived from qPCR data among patients with mild, moderate and severe dehydration is 3.25×10^7 (IQR 8.60×10^6 to 1.14×10^9), 1.05×10^8 (1.06×10^7 to 2.16×10^9) and 1.00×10^8 (8.34×10^6 to 4.41×10^9), respectively.
[d] Defined in Table 2.

Table 4. Effect of phage exposure on RDT positivity among cholera patients

Case definition	n	% RDT positive (n positive/ total) Exposed	Unexposed	OR[a]	CI[a]	*P* value[a]
Vc positive[a]						
All	197	46 (22/48)	46 (69/149)	0.981	0.508-1.88	0.954
Mild	43	6 (1/16)	15 (4/27)	0.383	0.019-2.91	0.411
Moderate	86	57 (8/14)	42 (30/72)	1.867	0.589-6.21	0.291
Severe	68	72 (13/18)	70 (35/50)	1.114	0.349-3.97	0.859
Vc positive or phage positive (ICP1,2,3)[a]						
All	259	25 (27/110)	46 (69/149)	**0.377**	**0.217-0.642**	**<0.001**
Mild	62	14 (5/35)	15 (4/27)	0.958	0.229-4.25	0.953
Moderate	113	20 (8/41)	42 (30/72)	**0.339**	**0.130-0.809**	**0.019**
Severe	84	41 (14/34)	70 (35/50)	**0.300**	**0.118-0.737**	**0.010**
Vc positive or ICP1 positive[a]						
All	218	32 (22/69)	46 (69/149)	**0.543**	**0.294-0.980**	**0.046**
Mild	57	13 (4/30)	15 (4/27)	0.885	0.189-4.13	0.872
Moderate	93	33 (7/21)	42 (30/72)	0.700	0.240-1.90	0.494
Severe	68	61 (11/18)	70 (35/50)	0.673	0.220-2.14	0.491
Vc positive or ICP3 positive[a]						
All	187	8 (3/38)	46 (69/149)	**0.099**	**0.023-0.292**	**<0.001**
Mild	32	20 (1/5)	15 (4/27)	1.44	0.065-13.6	0.770
Moderate	91	5 (1/19)	42 (30/72)	**0.078**	**0.004-0.409**	**0.015**
Severe	64	7 (1/14)	70 (35/50)	**0.033**	**0.002-0.188**	**0.002**

[a]Reference standard to define positive cholera cases for analysis within a given group. "*Vc* positive" is defined as positive by culture or qPCR.

Table 5. Effect of phage resistance on RDT positivity

Phage resistance detected (Ind5 or Ind6 positivity in *Vc*)[a]	RDT+ (n)	RDT- (n) [false negatives]	OR (CI)	*P* value[b]
Detected	58% (22)	16% (6)	**14.7 (2.83, 117)**	**0.002**
Not detected	5% (2)	21% (8)		

[a] Analyses on a subset of samples with *Vc* and phage (ICP1 or ICP3) in which metagenomics was performed and successful; sample characterization and methods were previously described[10]. Analyses do not account for antibiotic exposures.

[b] Fisher's exact test.

Table 6. Estimates of RDT performance in different modes of deployment

Approach	Unrestricted (comparator)	Use clinical exam	Use patient history and exam	Use clinical exam	Use patient history and exam
Restriction	None	Moderate and severe cases	Moderate and severe cases AND no reported antibiotic use	Severe cases	Severe cases AND no reported antibiotics use
Case definition (current gold standard): culture or qPCR for *Vc*					
Cases/total (%)	449 / 2078 (21.6)	374 / 1686 (22.2)	168 / 863 (19.5)	138 / 493 (28.0)	72 / 266 (27.1)
Sensitivity	0.46 (0.41, 0.51)	0.50 (0.45, 0.55)	0.54 (0.46, 0.61)	**0.63 (0.54, 0.71)**	**0.69 (0.57, 0.80)**
Specificity	0.85 (0.84, 0.87)	0.87 (0.85, 0.89)	0.86 (0.83, 0.89)	0.88 (0.85, 0.92)	0.86 (0.80, 0.91)
PPV_{obs}[b]	0.46 (0.42, 0.51)	0.53 (0.47, 0.58)	0.48 (0.41, 0.56)	**0.68 (0.59, 0.76)**	**0.65 (0.53, 0.75)**
NPV_{obs}[b]	0.85 (0.83, 0.87)	0.86 (0.84, 0.88)	0.88 (0.86, 0.91)	0.86 (0.82, 0.89)	0.88 (0.83, 0.93)
PPV_{50}[b]	0.76 (0.72, 0.79)	0.80 (0.76, 0.83)	0.79 (0.74, 0.84)	0.85 (0.78, 0.89)	0.83 (0.75, 0.90)
NPV_{50}[b]	0.61 (0.59, 0.64)	0.64 (0.61, 0.66)	0.65 (0.61, 0.69)	**0.71 (0.65, 0.76)**	**0.74 (0.66, 0.81)**
Case definition (expanded standard): culture or qPCR for *Vc* OR qPCR for ICP1/ICP3 phage					
Cases/ total (%)	567 / 2078 (27.3)	469 / 1686 (27.8)	216 / 863 (25.0)	173 / 493 (35.1)	89 / 266 (33.5)
Sensitivity	0.38 (0.34, 0.43)	0.41 (0.37, 0.46)	0.43 (0.36, 0.50)	**0.51 (0.43, 0.59)**	**0.57 (0.46, 0.68)**
Specificity	0.85 (0.83, 0.87)	0.87 (0.85, 0.89)	0.85 (0.82, 0.88)	0.88 (0.83, 0.91)	0.85 (0.79, 0.90)
PPV_{obs}[b]	0.49 (0.44, 0.54)	0.54 (0.49, 0.60)	0.49 (0.42, 0.57)	**0.69 (0.60, 0.77)**	**0.66 (0.55, 0.77)**
NPV_{obs}[d\b]	0.79 (0.77, 0.81)	0.79 (0.77, 0.81)	0.82 (0.79, 0.85)	0.77 (0.72, 0.81)	0.80 (0.73, 0.85)
PPV_{50}[b]	0.72 (0.68, 0.76)	0.76 (0.71, 0.80)	0.74 (0.68, 0.80)	0.80 (0.73, 0.86)	0.80 (0.70, 0.87)
NPV_{50}[b]	0.58 (0.55, 0.60)	0.60 (0.57, 0.62)	0.60 (0.56, 0.64)	0.64 (0.59, 0.69)	0.67 (0.59, 0.74)

[a] Shaded text represents the current unrestricted standard of RDT use using qPCR and culture for *Vc* as the reference standard. Bold text compares performance horizontally between unrestricted and restricted approaches; underlined text vertically compares sensitivity when the reference standard is expanded to include the detection of phages by qPCR (ICP1/3)

[b] Defined in Table 2.

SUPPLEMENTARY MATERIALS

Supplementary Figures

Figure S1. Study Map



Fig S1. Study site locations across Bangladesh. Red circles = RDT performed; gray circle = RDT not performed. Numbers in brackets correlate with site numbers in Table 1.

Figure S2. Sample processing diagram



Figure S2. Sample processing diagram. Schematic of the number of samples collected from patients admitted with diarrheal disease at the seven hospital locations (one per patient). RDTs were not performed on samples collected at the icddr,b (see methods) and parent study[47].

Figure S3. Antibiotic exposure.



Fig S3. Distribution of antibiotic exposure independent of RDT testing. **Left,** antibiotic detection by qualitative mass spectrometry among samples that were *Vc* culture positive, *Vc* PCR positive or phage PCR positive; see Fig S2. **Right,** self-reported exposure. Blue bars = antibiotic detected. MET = metronidazole, CIP= ciprofloxacin, AZI = azithromycin, DOX = doxycycline and/or tetracycline, NAL = nalidixic acid. Enumerations by *n* positive and percent positive are presented. An RDT was not performed on all samples included in this figure.

Supplementary Tables

Table S1. Comparison of RDT performance using different diagnostic criteria for cholera

	Vc (culture or qPCR)	*Vc* or ICP1 (qPCR)	*Vc* or ICP3 (qPCR)	*Vc* or ICP1 or ICP3[a]
Cases/total (%)[b]	449 / 2078 (21.6)	497 / 2078 (23.9)	520 / 2078 (25.0)	567 / 2078 (27.3)
Sensitivity	0.46 (0.41, 0.51)	0.43 (0.38, 0.47)	0.41 (0.37, 0.45)	0.38 (0.34, 0.43)
Specificity	0.85 (0.84, 0.87)	0.85 (0.83, 0.87)	0.85 (0.83, 0.87)	0.85 (0.83, 0.87)
PPV_{obs}[c]	0.47 (0.42, 0.51)	0.48 (0.43, 0.52)	0.48 (0.43, 0.53)	0.49 (0.44, 0.54)
NPV_{obs}[c]	0.85 (0.83, 0.87)	0.83 (0.81, 0.84)	0.81 (0.79, 0.83)	0.79 (0.77, 0.81)
PPV_{50}[c]	0.76 (0.72, 0.79)	0.74 (0.71, 0.78)	0.73 (0.70, 0.77)	0.72 (0.68, 0.76)
NPV_{50}[c]	0.61 (0.59, 0.64)	0.60 (0.57, 0.62)	0.59 (0.57, 0.62)	0.58 (0.55, 0.60)

[a] Independent of ICP2 detection

[b] Number positive for *Vc by* culture or qPCR (*tcpA*) as the gold reference standard over total number samples in grouping

[c] Subscript indicates the proportion of samples that were gold-standard positive in the given group for the calculation of each predictive value, with “obs”=observed and “50”=50%. For example, PPV_{50} or standardized positive predictive value indicates the positive predictive value of RDT in each group if 50% of that group was gold-standard positive for cholera.

Table S2. RDT performance as a function of antibiotic exposure

Exposure:	Reference	Antibiotic (any)	Ciprofloxacin		Azithromycin*		Doxycycline/Tetracycline*	
	No antibiotic	Exposure	Reported vs Detected	At effective Concentration[c]	Reported vs Detected	At effective Concentration[c]	Reported vs Detected	At effective Concent.[c]
Reported (all patients)								
Vc+/total(%)[a]	210 / 1122 (18.7)	239 / 956 (25.0)	159 / 568 (28.0)	---	58 / 289 (20.1)	---	---	---
Sensitivity	0.46 (0.39, 0.53)	0.46 (0.40, 0.53)	0.48 (0.40, 0.56)	---	0.43 (0.30, 0.57)	---	---	---
Specificity	0.84 (0.81, 0.86)	0.87 (0.85, 0.90)	0.89 (0.86, 0.92)	---	0.87 (0.82, 0.91)	---	---	---
PPV_{obs}[d]	0.39 (0.33, 0.46)	0.55 (0.48, 0.62)	0.63 (0.54, 0.71)	---	0.45 (0.32, 0.59)	---	---	---
NPV_{obs}[d]	0.87 (0.85, 0.89)	0.83 (0.80, 0.86)	0.81 (0.78, 0.85)	---	0.86 (0.81, 0.90)	---	---	---
PPV_{50}[d]	0.74 (0.69, 0.78)	0.79 (0.73, 0.83)	0.81 (0.75, 0.87)		0.77 (0.66, 0.85)			
NPV_{50}[d]	0.61 (0.57, 0.64)	0.62 (0.58, 0.66)	0.63 (0.58, 0.68)		0.60 (0.53, 0.67)			
Detected by Mass Spec (cholera patients only[b])								
Vc+/total(%)[a]	30 / 32 (93.8)	178 / 220 (80.9)	118 / 148 (79.7)	86 / 116 (74.1)	47 / 68 (69.1)	18 / 32 (56.3)	41 / 45 (91.1)	6 / 7 (85.7)
Sensitivity	0.67 (0.47, 0.83)	0.60 (0.53, 0.67)	0.55 (0.46, 0.64)	0.58 (0.47, 0.69)	0.49 (0.34, 0.64)	0.33 (0.13, 0.59)	0.61 (0.45, 0.7	0.83 (0.36, 1.00)
Specificity	1.00 (0.16, 1.00)	0.83 (0.69, 0.93)	0.83 (0.65, 0.94)	0.83 (0.65, 0.94)	0.76 (0.53, 0.92)	0.71 (0.42, 0.92)	0.75 (0.19, 0.9	0.00 (0.00, 0.97)
PPV_{obs}[d]	1.00 (0.83, 1.00)	0.94 (0.88, 0.97)	0.93 (0.84, 0.98)	0.91 (0.80, 0.97)	0.82 (0.63, 0.94)	0.60 (0.26, 0.88)	0.96 (0.80, 1.0	0.83 (0.36, 1.00)
NPV_{obs}[d]	0.17 (0.02, 0.48)	0.33 (0.24, 0.43)	0.32 (0.22, 0.44)	0.41 (0.29, 0.54)	0.40 (0.25, 0.57)	0.45 (0.24, 0.68)	0.16 (0.03, 0.4	0.00 (0.00, 0.97)
PPV_{50}[d]	1.00 (0.71, 1.00)	0.78 (0.68, 0.87)	0.77 (0.63, 0.87)	0.78 (0.63, 0.89)	0.67 (0.46, 0.85)	0.54 (0.21, 0.84)	0.71(0.46, 0.89	0.45 (0.10, 0.85)
NPV_{50}[d]	0.75 (0.52, 0.91)	0.68 (0.59, 0.75)	0.65 (0.55, 0.74)	0.67 (0.55, 0.77)	0.60 (0.44, 0.74)	0.52 (0.30, 0.73)	0.66(0.45, 0.83	0.00 (0.00, 1.00)

[a] Reference standard to define positive cholera cases is culture or qPCR (*tcpA*). Approach independent of phage exposure.
[b] Patients who met the following criteria had subsequent mass spectrometry: (i) culture positive for *Vc*, (ii) phage (ICP1,2,3) positive by PCR among culture-negative samples, or (iii) *Vc* positive by PCR among a random 10% of samples negative by culture for *Vc* and by PCR for phage (see methods).
[c] Concentration at or above the lowest minimal inhibitory concentration (see methods) and prior descriptions[51].
[d] Subscript indicates the proportion of samples that were gold-standard positive in the given group for the calculation of each predictive value, with "obs"=observed and "50"=50%. For example, PPV_{50} or standardized positive predictive value indicates the positive predictive value of RDT in each group if 50% of that group was gold-standard positive for cholera.

Table S3. Among *Vc* positive samples, impact of antibiotic exposure and resistance on RDT positivity (phage removed)[a]

Condition	RDT+	RDT- (false negatives)	OR (CI)	*P* value[b]
Ciprofloxacin (LCMS qual detection)[c]				
Exposed	30% (47)	22% (34)	0.705 (0.365-1.352)	0.3234
Not exposed	32% (49)	16% (25)		
Azithromycin (LCMS qual detection)				
Exposed	10% (15)	10% (16)	0.498 (0.223-1.105)	0.099
Not exposed	52% (81)	28% (43)		
Doxycycline (LCMS qual detection)[c]				
Exposed	12% (19)	7% (11)	1.077 (0.478-2.523)	1.000
Not exposed	50% (77)	31% (48)		
No azithromycin detected by qualitative LCMS[d]				
Isolate AZI resistant	25% (28)	14% (16)	0.750 (0.337-1.679)	0.54
Isolate AZI sensitive	43% (49)	18% (21)		
Azithromycin detected by qualitative LCMS[d]				
Isolate AZI resistant	29% (8)	21% (6)	1.333 (0.300 6.100)	1.000
Isolate AZI sensitive	25% (7)	25% (7)		

[a] Criteria to define cholera patients for subsequent mass spectrometry were (i) culture positive for *Vc*, (ii) phage (ICP1,2,3) positive by PCR among culture-negative samples, or (iii) *Vc* positive by PCR among a random 10% of samples negative by culture for *Vc* and by PCR for phage (see methods). Analyses removed samples with ICP1, 2, 3 detected. Those samples without RDT performed were excluded.
[b] Fisher's exact test
[c] Insufficient rates of resistance/sensitive strains for stratified analyses
[d] Among cholera patients in which the culture was positive and an isolate was obtained for AMR testing.

Table S4. RDT performance by severity and age group with culture or qPCR (*tcpA*) as the reference standard

	Mild (comparator)	Moderate	Severe	Moderate/Severe
0-11months				
Cases/total(%)[a]	25 / 167 (15.0)	13 / 142 (9.2)	4 / 39 (10.3)	17 / 181 (9.4)
Sensitivity	0.16 (0.05, 0.36)	0.38 (0.14, 0.68)	0.25 (0.01, 0.81)	0.35 (0.14, 0.62)
Specificity	0.73 (0.64, 0.80)	0.81 (0.73, 0.87)	0.89 (0.73, 0.97)	0.82 (0.76, 0.88)
PPV_{obs}[b]	0.09 (0.03, 0.22)	0.17 (0.06, 0.35)	0.20 (0.01, 0.72)	0.17 (0.07, 0.34)
NPV_{obs}[b]	0.83 (0.75, 0.89)	0.93 (0.86, 0.97)	0.91 (0.76, 0.98)	0.92 (0.87, 0.96)
PPV_{50}[b]	0.37 (0.21, 0.54)	0.66 (0.50, 0.80)	0.69 (0.27, 0.95)	0.67 (0.52, 0.80)
NPV_{50}[b]	0.46 (0.38, 0.55)	0.57 (0.46, 0.67)	0.54 (0.36, 0.72)	0.56 (0.47, 0.65)
1-4 years				
Cases/total(%)[a]	17 / 125 (13.6)	29 / 202 (14.4)	11 / 74 (14.9)	40 / 276 (14.5)
Sensitivity	0.06 (0.00, 0.29)	0.38 (0.21, 0.58)	0.45 (0.17, 0.77)	0.40 (0.25, 0.57)
Specificity	0.78 (0.69, 0.85)	0.82 (0.76, 0.87)	0.84 (0.73, 0.92)	0.83 (0.77, 0.87)
PPV_{obs}[b]	0.04 (0.00, 0.20)	0.26 (0.14, 0.42)	0.33 (0.12, 0.62)	0.28 (0.17, 0.42)
NPV_{obs}[b]	0.84 (0.75, 0.91)	0.89 (0.83, 0.93)	0.90 (0.79, 0.96)	0.89 (0.84, 0.93)
PPV_{50}[b]	0.21 (0.06, 0.47)	0.68 (0.54, 0.80)	0.74 (0.52, 0.90)	0.70 (0.58, 0.80)
NPV_{50}[b]	0.45 (0.36, 0.55)	0.57 (0.48, 0.65)	0.61 (0.46, 0.74)	0.58 (0.51, 0.65)
5-64 years				
Cases/total(%)[a]	32 / 97 (33.0)	185 / 797 (23.2)	118 / 351 (33.6)	303 / 1148 (26.4)
Sensitivity	0.41 (0.24, 0.59)	0.45 (0.38, 0.52)	0.67 (0.58, 0.75)	0.53 (0.48, 0.59)
Specificity	0.88 (0.77, 0.95)	0.89 (0.86, 0.91)	0.89 (0.85, 0.93)	0.89 (0.87, 0.91)
PPV_{obs}[b]	0.62 (0.38, 0.82)	0.55 (0.46, 0.63)	0.76 (0.67, 0.84)	0.63 (0.57, 0.69)
NPV_{obs}[b]	0.75 (0.64, 0.84)	0.84 (0.81, 0.87)	0.84 (0.79, 0.89)	0.84 (0.82, 0.87)
PPV_{50}[b]	0.77 (0.56, 0.91)	0.80 (0.74, 0.85)	0.86 (0.79, 0.91)	0.83 (0.79, 0.86)
NPV_{50}[b]	0.60 (0.47, 0.71)	0.62 (0.58, 0.66)	0.73 (0.67, 0.79)	0.66 (0.62, 0.69)
65+ years				
Cases/total(%)[a]	1 / 3 (33.3)	9 / 52 (17.3)	5 / 29 (17.2)	14 / 81 (17.3)
Sensitivity	1.00 (0.03, 1.00)	0.22 (0.03, 0.60)	0.40 (0.05, 0.85)	0.29 (0.08, 0.58)
Specificity	1.00 (0.16, 1.00)	0.95 (0.84, 0.99)	0.92 (0.73, 0.99)	0.94 (0.85, 0.98)
PPV_{obs}[b]	1.00 (0.03, 1.00)	0.50 (0.07, 0.93)	0.50 (0.07, 0.93)	0.50 (0.16, 0.84)
NPV_{obs}[b]	1.00 (0.16, 1.00)	0.85 (0.72, 0.94)	0.88 (0.69, 0.97)	0.86 (0.76, 0.93)
PPV_{50}[b]	1.00 (0.09, 1.00)	0.83 (0.39, 0.99)	0.83 (0.39, 0.99)	0.83 (0.54, 0.97)
NPV_{50}[b]	1.00 (0.09, 1.00)	0.55 (0.40, 0.70)	0.60 (0.38, 0.80)	0.57 (0.44, 0.69)

[a] Gold standard to define positive cholera cases is culture or qPCR (*tcpA*). Approach does not account for phage or antibiotics exposures.

[b.] Subscript indicates the proportion of samples that were gold-standard positive in the given group for the calculation of each predictive value, with "obs"=observed and "50"=50%. For example, PPV_{50} or standardized positive predictive value indicates the positive predictive value of RDT in each group if 50% of that group was gold-standard positive for cholera.

REFERENCES

1. Ali M, Nelson AR, Lopez AL, Sack DA. Updated global burden of cholera in endemic countries. *PLoS Negl Trop Dis* 2015; **9**(6): e0003832.
2. Cholera Upsurge. World Health Organization (WHO). 2024. https://www.who.int/emergencies/situations/cholera-upsurge (accessed Feb. 20, 2025).
3. Disease Outbreak News; Cholera - Global situation. World Health Organization (WHO); 2023. https://www.who.int/emergencies/disease-outbreak-news/item/2023-DON437 (accessed May 13, 2025).
4. Global deployment of rapid diagnostic tests to boost fight against cholera. World Health Organization (WHO). 2024. https://www.who.int/news/item/05-04-2024-global-deployment-of-rapid-diagnostic-tests-to-boost-fight-against-cholera (accessed Feb 20, 2025).
5. Hegde ST, Khan AI, Perez-Saez J, et al. Clinical surveillance systems obscure the true cholera infection burden in an endemic region. *Nat Med* 2024; **30**(3): 888-95.
6. Xu H, Zou K, Dent J, et al. Enhanced cholera surveillance to improve vaccination campaign efficiency. *Nat Med* 2024; **30**(4): 1104-10.
7. Nelson EJ, Harris JB, Morris JG, Jr., Calderwood SB, Camilli A. Cholera transmission: the host, pathogen and bacteriophage dynamic. *Nat Rev Microbiol* 2009; **7**(10): 693-702.
8. Nelson EJ, Chowdhury A, Flynn J, et al. Transmission of Vibrio cholerae is antagonized by lytic phage and entry into the aquatic environment. *PLoS Pathog* 2008; **4**(10): e1000187.

9. Nelson EJ, Grembi JA, Chao DL, et al. Gold Standard Cholera Diagnostics Are Tarnished by Lytic Bacteriophage and Antibiotics. *J Clin Microbiol* 2020; **58**(9).

10. Madi N, Cato ET, Abu Sayeed M, et al. Phage predation, disease severity, and pathogen genetic diversity in cholera patients. *Science* 2024; **384**(6693): eadj3166.

11. Nelson EJ, Nelson DS, Salam MA, Sack DA. Antibiotics for both moderate and severe cholera. *N Engl J Med* 2011; **364**(1): 5-7.

12. Islam MR. Single dose tetracycline in cholera. *Gut* 1987; **28**(8): 1029-32.

13. Gotuzzo E, Seas C, Echevarria J, Carrillo C, Mostorino R, Ruiz R. Ciprofloxacin for the treatment of cholera: a randomized, double-blind, controlled clinical trial of a single daily dose in Peruvian adults. *Clin Infect Dis* 1995; **20**(6): 1485-90.

14. Use of antibiotics for the treatment and control of cholera. World Health Organization (WHO) Global Task Force on Cholera Control (GTFCC). 2018. https://www.gtfcc.org/wp-content/uploads/2019/10/gtfcc-technical-note-on-use-of-antibiotics-for-the-treatment-of-cholera.pdf (accessed Feb 18, 2025).

15. Alexandrova L, Haque F, Rodriguez P, et al. Identification of Widespread Antibiotic Exposure in Patients With Cholera Correlates With Clinically Relevant Microbiota Changes. *J Infect Dis* 2019; **220**(10): 1655-66.

16. Saber MM, Shapiro BJ. Benchmarking bacterial genome-wide association study methods using simulated genomes and phenotypes. *Microb Genom* 2020; **6**(3).

17. Rouard C, Collet L, Njamkepo E, et al. Long-Distance Spread of a Highly Drug-Resistant Epidemic Cholera Strain. *N Engl J Med* 2024; **391**(23): 2271-3.

18. Lassalle F, Al-Shalali S, Al-Hakimi M, et al. Genomic epidemiology reveals multidrug resistant plasmid spread between Vibrio cholerae lineages in Yemen. *Nat Microbiol* 2023; **8**(10): 1787-98.

19. Seed KD, Yen M, Shapiro BJ, et al. Evolutionary consequences of intra-patient phage predation on microbial populations. *Elife* 2014; **3**: e03497.

20. Seed KD, Bodi KL, Kropinski AM, et al. Evidence of a dominant lineage of Vibrio cholerae-specific lytic bacteriophages shed by cholera patients over a 10-year period in Dhaka, Bangladesh. *MBio* 2011; **2**(1): e00334-10.

21. Seed KD, Faruque SM, Mekalanos JJ, Calderwood SB, Qadri F, Camilli A. Phase variable O antigen biosynthetic genes control expression of the major protective antigen and bacteriophage receptor in Vibrio cholerae O1. *PLoS Pathog* 2012; **8**(9): e1002917.

22. Yen M, Cairns LS, Camilli A. A cocktail of three virulent bacteriophages prevents Vibrio cholerae infection in animal models. *Nat Commun* 2017; **8**: 14187.

23. Beckman DA, Waters CM. Vibrio cholerae phage ICP3 requires O1 antigen for infection. *Infect Immun* 2023; **91**(9): e0002623.

24. Patel KM, Seed KD. Sporadic phage defense in epidemic Vibrio cholerae mediated by the toxin-antitoxin system DarTG is countered by a phage-encoded antitoxin mimic. *mBio* 2024; **15**(10): e0011124.

25. Oshiro RT, Dunham DT, Seed KD. The vibriophage-encoded inhibitor OrbA abrogates BREX-mediated defense through the ATPase BrxC. *J Bacteriol* 2024; **206**(11): e0020624.

26. LeGault K, Hays SG, Angermeyer A, et al. Temporal shifts in antibiotic resistance elements govern phage-pathogen conflicts. *Science* 2021; **373**(6554): 2020.12.16.423150.

27. Seed KD, Lazinski DW, Calderwood SB, Camilli A. A bacteriophage encodes its own CRISPR/Cas adaptive response to evade host innate immunity. *Nature* 2013; **494**(7438): 489-91.

28. Brenzinger S, Airoldi M, Ogunleye AJ, Jugovic K, Amstalden MK, Brochado AR. The Vibrio cholerae CBASS phage defence system modulates resistance and killing by antifolate antibiotics. *Nat Microbiol* 2024; **9**(1): 251-62.

29. McKitterick AC, Seed KD. Anti-phage islands force their target phage to directly mediate island excision and spread. *Nat Commun* 2018; **9**(1): 2348.

30. Jensen MA, Faruque SM, Mekalanos JJ, Levin BR. Modeling the role of bacteriophage in the control of cholera outbreaks. *Proc Natl Acad Sci U S A* 2006; **103**(12): 4652-7.

31. Faruque SM, Naser IB, Islam MJ, et al. Seasonal epidemics of cholera inversely correlate with the prevalence of environmental cholera phages. *Proc Natl Acad Sci U S A* 2005; **102**(5): 1702-7.

32. Faruque SM, Islam MJ, Ahmad QS, et al. Self-limiting nature of seasonal cholera epidemics: Role of host-mediated amplification of phage. *Proc Natl Acad Sci U S A* 2005; **102**(17): 6119-24.

33. King AA, Ionides EL, Pascual M, Bouma MJ. Inapparent infections and cholera dynamics. *Nature* 2008; **454**(7206): 877-80.

34. Pasricha CL, Monte AJ, Gupta SK. Season variations of cholera bacteriophage in natural waters and in man in Calcutta during the year 1930. *Indian Med Gaz* 1931; **66**: 543-50.

35. Silva-Valenzuela CA, Camilli A. Niche adaptation limits bacteriophage predation of Vibrio cholerae in a nutrient-poor aquatic environment. *Proc Natl Acad Sci U S A* 2019; **116**(5): 1627-32.

36. Page AL, Alberti KP, Mondonge V, Rauzier J, Quilici ML, Guerin PJ. Evaluation of a rapid test for the diagnosis of cholera in the absence of a gold standard. *PLoS One* 2012; **7**(5): e37360.

37. Dick MH, Guillerm M, Moussy F, Chaignat CL. Review of two decades of cholera diagnostics--how far have we really come? *PLoS Negl Trop Dis* 2012; **6**(10): e1845.

38. Sayeed MA, Paisie T, Alam MT, et al. Development of a Monoclonal Antibody to a Vibriophage as a Proxy for Vibrio cholerae Detection. *Infect Immun* 2022; **90**(8): e0016122.

39. Sayeed MA, Islam K, Hossain M, et al. Development of a new dipstick (Cholkit) for rapid detection of Vibrio cholerae O1 in acute watery diarrheal stools. *PLoS Negl Trop Dis* 2018; **12**(3): e0006286.

40. George CM, Rashid MU, Sack DA, et al. Evaluation of enrichment method for the detection of Vibrio cholerae O1 using a rapid dipstick test in Bangladesh. *Trop Med Int Health* 2014; **19**(3): 301-7.

41. Debes AK, Ateudjieu J, Guenou E, et al. Clinical and Environmental Surveillance for Vibrio cholerae in Resource Constrained Areas: Application During a 1-Year

Surveillance in the Far North Region of Cameroon. *Am J Trop Med Hyg* 2016; **94**(3): 537-43.

42. Ley B, Khatib AM, Thriemer K, et al. Evaluation of a rapid dipstick (Crystal VC) for the diagnosis of cholera in Zanzibar and a comparison with previous studies. *PLoS One* 2012; **7**(5): e36930.

43. Gupta P, Mankere B, Chekkoora Keloth S, Tuteja U, Pandey P, Chelvam KT. Increased antibiotic resistance exhibited by the biofilm of Vibrio cholerae O139. *J Antimicrob Chemother* 2018; **73**(7): 1841-7.

44. Perez-Saez J, Bhuiyan TR, Hegde ST, et al. Rethinking cholera diagnostic test performance, interpretation and evaluation: a field-based latent-class analysis in Bangladesh. *medRxiv* 2024: 2024.11.19.24317512.

45. The treatment of diarrhoea -- A manual for physicians and other senior health workers. 4th Rev. ed. Geneva, Switzerland: World Heath Organization. 2005.

46. Sayeed MA, Nabil IK, Bhattacharjee P, et al. Assembly and performance of a cholera RDT prototype that detects both Vibrio cholerae and associated bacteriophage as a proxy for pathogen detection. *J Clin Microbiol* 2025; **63**(2): e0144324.

47. Khan AI, Mack JA, Salimuzzaman M, et al. Electronic decision support and diarrhoeal disease guideline adherence (mHDM): a cluster randomised controlled trial. *Lancet Digit Health* 2020; **2**(5): e250-e8.

48. Khan AI, Qadri F. Epidemiology of cholera in Bangladesh: Findings from Nationwide Hospital-based Surveillance, 2014-2018. *CID* 2019.

49. Li D, Liu CM, Luo R, Sadakane K, Lam TW. MEGAHIT: an ultra-fast single-node solution for large and complex metagenomics assembly via succinct de Bruijn graph. *Bioinformatics* 2015; **31**(10): 1674-6.

50. Manual of Clinical Microbiology. 8th ed. Washington, D.C.: American Society for Microbiology Press; 2003.

51. Creasy-Marrazzo A, Saber MM, Kamat M, et al. Genome-wide association studies reveal distinct genetic correlates and increased heritability of antimicrobial resistance in Vibrio cholerae under anaerobic conditions. *Microb Genom* 2022; **8**(12).

52. Islam MT, Khan AI, Sayeed MA, et al. Field evaluation of a locally produced rapid diagnostic test for early detection of cholera in Bangladesh. *PLoS Negl Trop Dis* 2019; **13**(1): e0007124.

53. Team RC. R: A language and environment for statistical computing. R Foundation for Statistical Computing. 2021. http://www.R-project.org/ (accessed May 26, 2019.

54. J L. Eulerr: Area-Proportional Euler and Venn Diagrams with Ellipses. R package. 2024. https://CRAN.R-project.org/package=eulerr>.

55. M S, E S. EpiR: Tools for the Analysis of Epidemiological Data. R package version 2.0.78. <https://CRAN.R-project.org/package=epiR> (accessed March 16, 2025).

56. Levine AC, Gainey M, Qu K, et al. A comparison of the NIRUDAK models and WHO algorithm for dehydration assessment in older children and adults with acute diarrhoea: a prospective, observational study. *Lancet Glob Health* 2023; **11**(11): e1725-e33.